Podcasts about piis1470

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlwClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlwRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw#asco2025Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations. They discuss the disease burden of advanced melanoma with BRAF mutations, the key findings from the EBIN trial, and the future implications of the study findings, especially for a select sub-population of patients with advanced melanoma.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00133-0/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In de podcastserie Proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze speciale aflevering spreekt zij met dr. Paul Hengeveld over zijn proefschrift, getiteld: ‘Molecular risk stratification in chronic lymphocytic leukemia'. Paul vertelt hoe moleculaire risicostratificatie kan helpen in voorspellen van de prognose van patiënten met chronische lymfatische leukemie (CLL) en filosofeert over de toekomst van MRD (measurable residual disease) bij CLL. Paul heeft 27 maart 2024 zijn proefschrift succesvol verdedigd aan de Erasmus Universiteit bij prof. dr. Ton Langerak en co-promotoren dr. Mark-David Levin en dr. Peter Westerweel. Hij kreeg dit jaar tijdens de hematologiedagen het Jaap Steenbergen Stipendium voor het beste hematologieproefschrift van 2024.Referenties Inspiratietip: Belgische televisieserie - Met gevoel voor tumor Prognose CLL – THEMIS2 MRD CLL10 Sequentiële MRD HOVON-139 FLAIR-studie

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial.This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risks, patient experiences, and the potential implications for clinical practice and health policy.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00100-7/fulltext?dgcid=buzzsprout_tlv_podcast_30-04-25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In de podcastserie proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze aflevering spreekt zij met dr. Teska Schuurman over haar proefschrift, getiteld: “Tailored care in fertile women with cancer”. Teska bespreekt de aanleiding voor haar onderzoek en verschillende studies die ze deed om de behandeling van AYA's (adolescents and young adults) te kunnen personaliseren om fertiliteit te kunnen behouden indien gewenst. Teska heeft op 24 maart haar proefschrift succesvol verdedigd aan de Universiteit van Amsterdam bij dr. Christianne Lok, dr. Nienke van Trommel en prof. dr. Frederic Amant.Referenties Boek: Even ontspannen, mevrouw – Mieke Kerkhof Tamoxifen in de zwangerschap.Literatuurstudie fertiliteit sparende chirurgie voor gynaecologische tumoren. Fertiliteit sparende chirurgie voor voorstadium cervixcarcinoom (AIS). Individualiseren van follow-up na fertiliteit sparende chirurgie voor cervixcarcinoom.

Today, after a brief discussion of shows Ali and Asif have been watching lately – including ‘One Day' and ‘Adolescence' (as well as shows they bailed on… ‘Breaking Bad' and ‘The White Lotus') – they discuss ‘Apple Cider Vinegar' and Belle Gibson (7:43). They go over Belle Gibson's rise from Instagram “Wellness Warrior” to being exposed as faking having brain cancer. They then discuss the Netflix TV show based on Belle Gibson's story ‘Apple Cider Vinegar'. They discuss how the show weaves in Belle's story with the fictionalized character of Milla who is closely based on Jessica Ainscough, a prominent Australian influencer who billed herself as Wellness Warrior who did in fact have cancer. They then give their thoughts on the show including Kaityn Dever's amazing performance.    Then, based on the recent outbreaks in North America, Ali asks Asif about Measles (26:48). Asif talks about what it is and how it is one of the most contagious infectious diseases. Asif then talks about who is at risk of contracting measles including the unvaccinated, children under age 1 year and the immunocompromised. Asif goes over the symptoms and the potential fatal complications. He then goes over how it is treated. Then Ali asks Asif about the reasons for declining vaccination rates.    The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.    Music courtesy of Wataboi and 8er41 from Pixabay   Contact us at doctorvcomedian@gmail.com   Follow us on Social media: Twitter: @doctorvcomedian Instagram:  doctorvcomedian   Show Notes: Unmasking Belle Gibson: The real story of the infamous wellness scammer: https://www.youtube.com/watch?v=fahOX8VBXCc The Cancer Scams That Foreshadowed MAHA: https://www.newyorker.com/culture/cultural-comment/the-cancer-scams-that-foreshadowed-maha The Search for Instagram's Worse Con Artist: https://www.netflix.com/ca/title/81987249 The rise and fall of the wellness warriors: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30207-9/abstract A play-by-play of how measles outbreaks can spiral out of control: https://www.cbc.ca/news/health/measles-second-opinion-march-2025-1.7476500 Ask an expert: Why are we seeing measles outbreaks across Canada and who should get vaccinated? https://www.dal.ca/news/2025/03/27/measles-outbreak-expert.html Measles: https://www.ncbi.nlm.nih.gov/books/NBK448068/ Measles vaccines: Canadian Immunization Guide: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-12-measles-vaccine.html

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125737 --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS Drs. Burgoyne and Mizrahi provide a primer on immunotherapy and explain how they communicate the principles of this treatment to their patients. Dr. Du discusses the Imbrave clinical trial and how recent studies have shown improved overall survival when immunotherapeutic agents are used, especially when multiple agents targeting various pathways are employed. When choosing between different regimens, the doctors consider factors such as the patient's underlying liver function, symptom burden, and prior treatments. Importantly, the doctors also discuss contraindications to immunotherapy, including a history of organ transplant, autoimmune disease, and poor performance status—all of which put patients at high risk for deterioration with this treatment. The treatment of patients with poor liver function remains controversial, as underlying cirrhosis may prevent the recovery of liver function. Dr. Berman outlines recent clinical trials studying the effects of transarterial chemoembolization (TACE) combined with immunotherapy. Finally, the doctors discuss the future of HCC treatment and the benefits of continued innovation in both interventional and medical oncology. --- TIMESTAMPS 00:00 - Introduction to Immunotherapy 04:32 - Notable Clinical Trials 13:39 - HCC Etiology and Immunotherapy Outcomes 18:43 - Contraindications for Immunotherapy 23:05 - Adverse Effects from Treatment 25:14 - Combination Therapy 36:22 - Considerations for Immunotherapy Dosing 40:26 - The Future of HCC Treatment --- RESOURCES Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, IMbrave150 Trial (Finn et al, 2020): https://pubmed.ncbi.nlm.nih.gov/32402160/ Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, HIMALAYA Trial (Abou-Alfa et al, 2022): https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial (Yau, 2022): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/abstract Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW (Galle, 2024): https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4008 Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment (Llovet, 2022): https://pubmed.ncbi.nlm.nih.gov/35119481/ Find this episode on BackTable.com for more resources.

In de podcastserie proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze aflevering spreekt zij met dr. Lisette Rozeman over haar proefschrift, getiteld: “Improving outcome of melanoma patients upon immunotherapy”. Lisette vertelt over de verschillende studies met immunotherapie, die zij samen met haar promotor prof. dr. Christian Blank heeft opgezet, gecoördineerd en geanalyseerd, en die de behandeling van patiënten met een melanoom significant hebben veranderd. Lisette heeft op 7 januari jl. haar proefschrift succesvol verdedigd aan de Universiteit van Leiden. Referenties Podcast: The fellow on call OPACIN: Blank CU, et al. Nature Medicine 2018;24:1655–6. OPACIN-neo: Rozeman EA, et al. Lancet Oncol 2019;20:948-60. SWOG 1801: Patel SP, et al. N Eng J Med 2023;388:813-23. NADINA: Blank CU, et al. N Eng J Med 2024;391:1696-708. IMPEMBRA: Rozeman EA, et al. J Immunother Cancer 2023;11:e006821. Sequentiële combinatietherapie: Reijers IL, et al. https://onlinelibrary.wiley.com/doi/10.1111/pcmr.12835 Antistoffen en toxiciteit 1: De Moel EC, et al. Cancer Immunol Res 2019;7:6-11. Antistoffen en toxiciteit 2: Borgers JS, et al. J Immunother Cancer 2024;12:e009215.

In this episode of SurgOnc Today®, Dr. Julie Hallet, Chair of the HPB Disease Site Work Group, and Dr. Patricio Polanco, Vice-Chair of the HPB Disease Site Work Group, are joined by Drs. Sajid Khan from Yale School of Medicine and Dr. Cecilia Ethun from UT Southwestern. They will wrap the 2024 HPB year by reviewing the top HPB surgical oncology published this year.  References/Resources: #10: AMPLIFY https://www.nature.com/articles/s41591-023-02760-3   #9: Adjuvant therapy for IPMN-derived PDAC - https://ascopubs.org/doi/abs/10.1200/JCO.23.02313   #8: HELIX https://jamanetwork.com/journals/jama/fullarticle/2822555  #7: CAMINO  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00572-7/fulltext  #5 : PANDAS/PRODIGE https://www.annalsofoncology.org/article/S0923-7534(24)03884-5/fulltext

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.Read the full Articles here:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonchttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial'.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

The  @OncoAlert Round Up Covering July 26-Aug 1, 2024   REGISTER at http://Oncoalert360.com or https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration DiscussingShield Blood test FDAApproved for #ColorectalCancer Screeninghttps://ascopost.com/news/july-2024/guardant-health-s-shield-blood-test-approved-by-the-fda-as-a-primary-screening-option-for-colorectal-cancer/INSIGHT Trial in #NSCLC https://thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00270-5/abstractCombining PSMA-PETand PROMISE in #ProstateCancer https://sciencedirect.com/science/article/pii/S1470204524003267Review in RCC #KidneyCancer @b_szabados @drfrankiejs @tompowles1 https://thelancet.com/journals/lancet/article/PIIS0140-6736(24)00917-6/abstract Immune & Gene Expressionin ER Low & Neg #BreastCancer by @vitti10 https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djae178/7724836?searchresult=1&login=false Top Advances of the year: #Immunotherapy & #EndometrialCancer @BanerjeeSusana @PelegHasson https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35417ASCOGuidelines on cannabis in Adults Cancerhttps://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35461?af=R

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Tatuajes y cáncer Marcos Vázquez de Fitness Revolucionario https://www.instagram.com/p/C8OskyCNMeh/?igsh=MW96NjN2dWFhdTNkdg==https://ascopost.com/news/may-2024/are-tattoos-linked-to-a-heightened-risk-of-lymphoma/#:~:text=“After%20taking%20into%20account%20other,affect%20the%20risk%20of%20lymphoma.Apúntate gratis desde: https://borjagiron.comHe investigado https://onlinelibrary.wiley.com/doi/10.1111/exd.13383https://www.americanjournalofsurgery.com/article/S0002-9610(17)30347-1/fulltexthttps://link.springer.com/article/10.1007/s00266-017-1002-0https://www.dovepress.com/tattoo-associated-viral-infections-a-review-peer-reviewed-fulltext-article-CCIDhttps://journals.lww.com/dermatologicsurgery/abstract/2002/10000/tattoo_associated_dermatoses__a_case_report_and.15.aspxhttps://link.springer.com/article/10.1007/s12016-016-8532-0https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70340-0/abstractBorja, pero mucha gente tiene tattoos, incluso famosos y futbolistas. Mucha gente fuma también. Los tatuadores obviamente no le gusta que la gente compara esta información. A los que tienen tatuajes tampoco les sienta bien pero es lo que es. Pasa lo mismo con el vino. Cuando compartí que el alcohol es malo y da igual si es de vino o donde sea como si el cuerpo identificara tipos de alcohol y entonces dijera que este alcohol sí lo acepto. Independientemente de los estudios estás poniendo en tu cuerpo una sustancia externa a él y tratará de expulsarla. Pero no puede. Lucha las 24h y eso hace que esté en estrés constante. A mí me da igual. Yo no tengo tatuajes. Mi recomendación: No te hagas tatuajes. Si ya los tienes cuídate más que nadie. Deja alcohol, tabaco… duerme bien. Nada de carbohidratos. Dieta keto. Deporte. Sol (vive en la playa o donde disfrutes). Buenas relaciones. Trabaja en algo que te guste.Si te lo quieres hacer o hacerte más piénsatelo bien. Elige un sitio experto y revisa la tinta. Es para toda la vida. Quítatelos con láser. Mi prima tattoo del rayo vallecano que tiene rayo rojo y tiene inflamado.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/los-ultimos-dias--2659766/support.

Refrigerante zero associado a risco grave de doença cardíaca, será? Você sabia que aquele refrigerante zero que parece tão inocente pode ser uma bomba-relógio para sua saúde? Sim, mesmo aquelas opções 'sem açúcar' podem esconder perigos que afetam não apenas seu coração, mas sua mente e até suas futuras gerações! Existe limite seguro para tomar? Quantos Copos de Refrigerante Zero Até Que Seja Tarde Demais? Fique comigo e descubra por que repensar sua próxima lata de refrigerante pode ser a decisão mais saudável que você fará! Capítulos: 00:00 Introdução 00:34 Refrigerante e fibrilação atrial 02:33 Estudo publicado sobre refrigerante Zero/diet 05:02 Estudo Refrigerante Zero/diet bactérias intestinais 06:48 Refrigerante e o perigos dos ingredientes 08:38 Riscos de saúde cardiovascular e mental 10:26 Riscos do Aspartame Referências: https://www.ahajournals.org/doi/10.1161/CIRCEP.123.012145 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211390/#ABS1title https://newsroom.heart.org/news/sweetened-drinks-linked-to-atrial-fibrillation-risk https://www.med.ubc.ca/news/harmful-gut-bacteria-feed-on-sugars-in-the-intestinal-lining/ https://www.mdpi.com/1420-3049/23/10/2454 https://www.businessinsider.com/artificial-sweeteners-aspartame-and-sucralose-damage-gut-bacteria-e-coli-2018-10 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856475/#s18title https://pubmed.ncbi.nlm.nih.gov/18800291/ https://www.mdpi.com/1422-0067/22/18/9863 https://www.nytimes.com/2017/01/13/opinion/sunday/big-sugars-secret-ally-nutritionists.html https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784545 https://plan.core-apps.com/eb2018/abstract/382e0c7eb95d6e76976fbc663612d58a https://www.sciencedirect.com/science/article/abs/pii/S0002916524000017#preview-section-abstract https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094715#abstract0 https://www.pnas.org/doi/10.1073/pnas.2213120119#executive-summary-abstract https://www.nbcnews.com/health/cancer/foods-contain-aspartame-artificial-sweetener-possible-carcinogen-rcna93913 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00341-8/abstract https://pubmed.ncbi.nlm.nih.gov/16129618/ https://ajcn.nutrition.org/article/S0002-9165(23)39821-6/abstract https://pubmed.ncbi.nlm.nih.gov/8373935/ https://www.nature.com/articles/1602866 Tópicos Principais do vídeo Quantos Copos de Refrigerante Zero/Diet Até Que Seja Tarde Demais? 1. Relação entre refrigerantes e riscos à saúde cardíaca, incluindo a fibrilação atrial. 2. Efeitos adversos dos refrigerantes 'diet' e 'zero' na saúde cardiovascular e geral. 3. Impacto dos adoçantes artificiais sobre a microbiota intestinal e a saúde celular. 4. Associação entre consumo de bebidas adoçadas e aumento do risco de doenças cardiovasculares e mentais. 5. Descobertas recentes sobre adoçantes como o aspartame, incluindo riscos de ansiedade e potencial carcinogênico. Seja membro deste canal e ganhe benefícios, conteúdo exclusivo, acesso ao grupo de Whatsapp e 2 lives exclusivas mensais: https://www.youtube.com/channel/UCRLKi_9gQNthwlKi70qi54g/join ⚠️AVISO LEGAL⚠️ A informação médica contida nesse vídeo é somente para fins de informação geral e não deve ser usada para qualquer finalidade de diagnóstico ou tratamento. Esta informação NÃO cria nenhuma relação médico-paciente e não deve ser usado como substituto de diagnóstico ou tratamento profissional. Por favor, consulte seu médico antes de tomar qualquer decisão sobre cuidados de saúde e NÃO pare nenhuma medicação sem o consentimento do seu médico. A Medicina é uma ciência em constante mudança, os vídeos são produzidos baseados nos Artigos Científicos mais recente até a data. De acordo com Art. 8º da Resolução CFM 1974/11 de Publicidade do Código de Ética Médica, os vídeos têm somente caráter de prestar informações de fins estritamente educativos. Dr. Alain Dutra -

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00071-8?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.'Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.Here are the shownotes:1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutationhttps://www.nejm.org/doi/full/10.1056/nejmoa1614359 3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext 4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupshttps://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction 5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.2017.72.8618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyhttps://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs 7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AMLhttps://www.nejm.org/doi/full/10.1056/nejmoa1902688 8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.22.00602?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023. 10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30455-1/fulltext?dgcid=raven_jbs_etoc_email

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium's recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.Read the full Policy Review:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make strides in patient care with a phase 1 study that may be lost in no-man land or could harbour a shift in trial design with antibody drug conjugates. Today, we discuss the following trials:Articles discussed in this episode. Subscription may be required:Keynote 641 (Pembrolizumab + enzalutamide in the metastatic castrate-resistant prostate cancer sphere)https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2819%2930688-6/fulltextPSMAfore trial (LuPSMA in taxane naive patients)https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639061MAGNITUDE Study (Niraparib and abiraterone)https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639153The DAD study (sacituzumab govitecan (SG) plus enfortumab vedotin (EV)https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00563-6/fulltextFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Hosted on Acast. See acast.com/privacy for more information. Hosted on Acast. See acast.com/privacy for more information.

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, Anthony and Bernie chat with Chris Booth, MD, and Aaron "Papa Heme" Goodman, MD, to talk about the Common Sense Oncology movement! Join the Common Sense Oncology movement at this link (it's free!): https://commonsenseoncology.org/ Lancet Oncol paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00319-4/fulltext

To start the episode, Ali and Asif discuss the controversy surrounding country singer Miranda Lambert chastising concertgoers for taking selfies (0:48). Then, after a brief digression on Dana Carvey's Joe Biden impression, Asif asks Ali about the surprise hit TV show ‘Jury Duty' (10:32). They discuss the background of the show and how it is a combination of ‘The Office' and ‘The Joe Schmo Show'. They then discuss how the show did not make much of a splash when it first debuted, but then gained buzz via TikTok. Ali and Asif then discuss the show's reception and  their thoughts on the show. They then discuss the Emmy nominations the show has received, including James Marsden for best supporting actor…for playing himself. Then the guys RE-discuss artificial sweeteners because of a new press-release issued by the WHO on the possible carcinogenic effects of aspartame (37:45). Asif explains how it was a joint press release, highlighting findings about   aspartame are released today by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) Joint Expert Committee on Food Additives (JECFA). Overall, Asif explains how the IARC found “limited evidence” for carcinogenicity in humans aand classified aspartame as possibly carcinogenic to humans. He then explains that JECFA reaffirmed the acceptable daily intake of 40 mg/kg body weight (ie an adult weighing 70kg would need to consume more than 9–14 cans per day to exceed the acceptable daily intake). Asif clarifies how  the agencies' statements are "complementary" in that the two groups work differently, and have a different aim: while IARC flags a potential hazard based on even limited evidence, JECFA assesses the real-life risk.   A reminder that the pod will be taking a month off in August. Look for new episodes coming your way on Sept 8, 2023!   The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.    Music courtesy of Wataboi and 8er41 from Pixabay   Contact us at doctorvcomedian@gmail.com   Follow us on Social media: Twitter: @doctorvcomedian Instagram: doctorvcomedian   Show notes: Miranda Lambert has a point: https://www.avclub.com/miranda-lambert-scolds-fans-at-show-backlash-1850651000 How Jury Duty Orchestrated the Trial of a Lifetime: https://www.vulture.com/article/jury-duty-interview.html How 'Jury Duty' completely faked a trial in real courtroom with a narcissistic James Marsden: https://www.usatoday.com/story/entertainment/tv/2023/04/08/jury-duty-feevee-series-fakes-civil-trial-james-marsden/11610571002/ Their Show Flew Under the Radar. TikTok Blew It Up: https://www.nytimes.com/2023/06/08/arts/television/jury-duty-freevee.html How Jury Duty became the surprise comedy breakout of the year: https://www.theguardian.com/tv-and-radio/2023/jul/17/show-jury-duty-amazon-freevee-tiktok What is aspartame and what do the new WHO rulings mean? https://www.reuters.com/business/healthcare-pharmaceuticals/what-is-aspartame-what-do-new-who-rulings-cancer-consumption-mean-2023-07-13/ Opinion: What the WHO aspartame findings mean for your diet: https://www.cnn.com/2023/07/21/opinions/aspartame-sweetener-diet-world-health-organization-branca/index.html Does Aspartame Cause Cancer or Is It Safe to Consume? The Latest Evidence About the Artificial Sweetener: https://time.com/6294701/aspartame-cancer-sweetener-studies/ Ninety-sixth meeting - Joint FAO/WHO Expert Committee on Food Additives (JECFA): https://www.who.int/publications/m/item/ninety-sixth-meeting-joint-fao-who-expert-committee-on-food-additives-(jecfa) IARC Monographs Hazard Classification: https://www.iarc.who.int/wp-content/uploads/2023/06/IARC_MONO_classification_2023_updated.png Carcinogenicity of aspartame, methyleugenol, and isoeugenol: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00341-8/fulltext Summary of findings of the evaluation of aspartame at the International Agency for Research on Cancer (IARC) Monographs Programme's 134th Meeting, and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) 96th meeting: https://www.who.int/publications/m/item/summary-of-findings-of-the-evaluation-of-aspartame-at-the-international-agency-for-research-on-cancer-(iarc)-monographs-programme-s-134th-meeting--and-the-joint-fao-who-expert-committee-on-food-additives-(jecfa)-96th-meeting

“Aspartam kommer på WHO's kræftliste.” Det var én af de mange overskrifter, man kunne læse, da det for to uger siden blev afsløret, at Verdenssundhedsorganisationen ville klassificere sødemidlet som ‘muligvis kræftfremkaldende'. Nu er WHO udkommet med deres begrundelse – men siger samtidig, at det ikke er skadeligt at indtage. Og det har – forståeligt nok – skabt både frygt og forvirring. I denne episode gennemgår vi WHO pressemeddelselse samt de forskellige instanser, IARC og JECFA, der er involveret i asapartam-udmeldingen og hvad der egentlig er op og ned på kategoriseringen af aspartam. Vi besvarer ud fra det spørgsmålet: Er der grund til bekymring for aspartam skulle være skadeligt at indtage? Hvis du vil støtte podcasten, så finder du vores sponsor Zetland lige her. Du får to måneders lytbar, reklamefri, dommedagsfri kvalitetsjournalistik for 50 kroner i alt. Det er under en tredjedel af normalprisen: zetland.dk/slutmedforbudt Ting, vi nævner i podcasten: Elsøes Instagram-opslag, der opsummerer hele sagen: https://www.instagram.com/p/CutgghKNoKh/  Pressemeddelelsen fra WHO, der både indeholder konklusionen fra IARC og JECFA: https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released Artiklen i Lancet, der indeholder IARC's begrundelse for vurderingen af aspartam: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00341-8/fulltext JECFA's begrundelse for stadig at vurdere, at aspartam er sikkert at indtage: https://www.who.int/publications/m/item/ninety-sixth-meeting-joint-fao-who-expert-committee-on-food-additives-(jecfa) IARC's database over alt, de har har vurderet til dato: https://monographs.iarc.who.int/list-of-classifications/  EFSA's kritik af de italienske aspartam-forsøg, der – som de eneste – konkluderede, at aspartam var kræftfremkaldende i mus: https://www.efsa.europa.eu/en/news/efsa-assesses-new-aspartame-study-and-reconfirms-its-safety 

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00157-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00072-4/fulltext?dgcid=buzzsprout_icw_podcast_lanonc_lancetContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

De novo metastatic breast cancer represents 6% of all new breast cancer diagnoses. This figure has not changed at all over the past 20 years; however, systemic therapy options have evolved dramatically during this time and have significantly increased life expectancy for these patients. While surgical management of the primary tumor in the setting of metastatic disease has typically been reserved for palliative indications, surgeons are now being asked to consider resecting the primary tumor to potentially increase overall survival. In this episode, we will use a case study to examine the data that should inform our conversations and decisions when we encounter patients with metastatic breast cancer who are interested in having their primary tumor resected. Links: Khan, S.A., S. Schuetz, and O. Hosseini (2022). Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review. Ann Surg Oncol; 29: 5811-5820. https://link.springer.com/article/10.1245/s10434-022-11900-x Khan, S.A. et al (2022). Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). J Clin Oncol; 40(9): 978-987. https://ascopubs.org/doi/10.1200/JCO.21.02006?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Badwe, R. et al (2015). Locoregional treatment versus no treatment of the primary tumor in metastatic breast cancer: an open-label randomized controlled trial. Lancet Oncol; 16: 1380-1388. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00135-7/fulltext Fitzal, F. et al (2019). Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg; 269(6): 1163-1169. https://journals.lww.com/annalsofsurgery/Abstract/2019/06000/Impact_of_Breast_Surgery_in_Primary_Metastasized.24.aspx Soran, A. et al (2018). Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol; 25: 3141-3149. https://link.springer.com/article/10.1245/s10434-018-6494-6 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out other breast surgery episodes here: https://behindtheknife.org/podcast-category/breast/

Today, our intrepid trio once more plunge down 20,000 leagues, exploring the confusing depths, hoping to answer one question: is there any evidence to support using systemic therapy in patients with potentially resectable oligometastatic colorectal cancer? The answer will take them to many dark, barely-explored corners of their profession and will raise more questions than answers. Following in the forebears of many explorers, it may drive them completely mad, or at least madder than they already are. But, to paraphrase Captain Nemo of the Nautilus: "the Earth does not want new continents, but new evidence for patients with resectable metastatic colorectal cancer."Links to studies discussed in this episode (subscription may be required):OLIVIA: https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035Falcone et al.: https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedTRIBE: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20ItalianFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Concluding their Journey to the Centre of the Brain, Michael and Josh tackle one of the most challenging and difficult cancers in modern oncology: high-grade gliomas. All of the usual suspects are here: irrevocable, progressive disease, limited treatment options and a gulf in evidence so large it makes the Grand Canyon look like a muddy footprint. All in all, not the most optimistic of OftiM episodes, but Josh and Michael will tackle it anyway so you don't have to. And remember: always refer your fit GBM patients to a friendly neighbourhood trials unit near you!Links to studies discussed in this episode (subscription may be required):EORTC 26981-22981 NCIC CE3 (aka the “Stupp study"): https://www.nejm.org/doi/full/10.1056/nejmoa043330RTOG 0825: https://www.nejm.org/doi/full/10.1056/nejmoa1308573Brada et al: https://ascopubs.org/doi/full/10.1200/JCO.2009.27.1932?role=tabTaal et al: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70314-6/fulltextWick et al: https://www.nejm.org/doi/full/10.1056/nejmoa1707358For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOncIf you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comVisit us at your new website www.inquisitiveonc.com for our latest episodes, links to resources and musings!Art courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Note: This podcast is for educational purposes only. If you are unwell seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Drs Sumanta Pal and Martin Voss discuss second-line treatment of renal cell carcinoma, including current studies and agents used in the refractory setting. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968745). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Renal Cell Carcinoma Treatment & Management https://emedicine.medscape.com/article/281340-treatment Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61613-9/fulltext Cabozantinib Versus Everolimus in Advanced Renal-Cell Carcinoma https://www.nejm.org/doi/full/10.1056/NEJMoa1510016 CANTATA: Primary Analysis of a Global, Randomized, Placebo (Pbo)-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib Versus Pbo + Cabozantinib in Advanced/Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Who Progressed on Immune Checkpoint Inhibitor (ICI) or Anti-Angiogenic Therapies. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4501 FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30735-1/fulltext Lenvatinib, Everolimus, and the Combination in Patients With Metastatic Renal Cell Carcinoma: A Randomised, Phase 2, Open-Label, Multicentre Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00290-9/fulltext A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) https://clinicaltrials.gov/ct2/show/NCT04338269 TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(20)42472-X Kidney Cancer Research Summit https://kcrs.kidneycan.org/

Neste segundo episódio da série final da segunda temporada, falando sobre relações entre causas e efeitos, foi comentar os resultados de uma coorte publicada no Lancet no início de dezembro agora de 2022, demonstrando uma relação entre a exposição em crianças e adolescentes à exames de tomografias de pescoço e cabeça e o desenvolvimento de neoplasias no futuro. E é sobre estas relações demonstradas que vou puxar a discussão sobre alguns dos nove critérios sugeridos pelo grande epidemiologista e estatístico inglês em 1965, após seu importante artigo publicado: “O Ambiente e a Doença: Associação ou Causalidade?”, buscando demonstrar as diferenças entre os termos associação e causalidade. Artigo disponível em: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00655-6/fulltext

Oncologists love pushing the limits of what is possible for our patients. To celebrate this and the 20th episode of Oncology for the Inquisitive Mind, Michael and Josh explore the heights of pioneering treatment for early-stage triple-negative breast cancer (TNBC). A notoriously resistant cancer with no known targetable lesions that affect younger women on average, The BrighTNess trial, Keynote 522 and Create-X show just how far the treatment landscape has changed in the last five years.Tune into our final episode for the year! We will return in early 2023 with more content, interviews and hilarious banter.On a final note, Dr Michael Fernando has been admitted to the Royal Australian College of Physicians (RACP), the equivalent of being board certified! Michael has completed this arduous training and is now a fully-fledged Medical Oncologist! Do not distress listeners. Despite no longer being a trainee, Michael will continue on as presenter and host extraordinaire for this podcast.Links to studies discussed in this episode (subscription may be required):BrighTNess trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-6/fulltextKeynote 522: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549Create-X: https://www.nejm.org/doi/full/10.1056/NEJMoa1612645For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

De novo metastatic breast cancer represents 6% of all new breast cancer diagnoses. This figure has not changed at all over the past 20 years; however, systemic therapy options have evolved dramatically during this time and have significantly increased life expectancy for these patients. While surgical management of the primary tumor in the setting of metastatic disease has typically been reserved for palliative indications, surgeons are now being asked to consider resecting the primary tumor to potentially increase overall survival. In this episode, we will use a case study to examine the data that should inform our conversations and decisions when we encounter patients with metastatic breast cancer who are interested in having their primary tumor resected. Links: §  Khan, S.A., S. Schuetz, and O. Hosseini (2022). Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review. Ann Surg Oncol; 29: 5811-5820. https://link.springer.com/article/10.1245/s10434-022-11900-x §  Khan, S.A. et al (2022). Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). J Clin Oncol; 40(9): 978-987. https://ascopubs.org/doi/10.1200/JCO.21.02006?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed §  Badwe, R. et al (2015). Locoregional treatment versus no treatment of the primary tumor in metastatic breast cancer: an open-label randomized controlled trial. Lancet Oncol; 16: 1380-1388. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00135-7/fulltext §  Fitzal, F. et al (2019). Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg; 269(6): 1163-1169. https://journals.lww.com/annalsofsurgery/Abstract/2019/06000/Impact_of_Breast_Surgery_in_Primary_Metastasized.24.aspx §  Soran, A. et al (2018). Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol; 25: 3141-3149. https://link.springer.com/article/10.1245/s10434-018-6494-6 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our other clinical challenges episodes here: https://behindtheknife.org/podcast-series/clinical-challenges/

In this episode, Josh and Mikey travel back millions of years to a time when dinosaurs roamed the Earth, as recent research has demonstrated, unmolested by cancer. Then they come crashing back to the present to discuss this week's topic, metastatic colorectal cancer. Will they discover secrets hidden across the aeons? Was the secret to cancer treatment hidden in the bones of our scaled precursors? No, of course not. But there will be a lot of information on the improving treatment of colorectal cancer, which has not taken millions of years to advance. Oh, and Michael does a passable Richard Attenborough.Links to studies discussed in this episode (subscription may be required):FIRE-3: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70330-4/fulltextKEYNOTE 177: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699BEACON: https://www.nejm.org/doi/full/10.1056/NEJMoa1908075Epidemiological Study of Tumours in Dinosaurs: https://link.springer.com/article/10.1007/s00114-003-0473-9For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

  Vidcast:  https://youtu.be/SfP3br735Mk   The brain is surrounded by a barrier that protects it from blood-borne toxins.  Usually a benefit, it complicates the treatment of brain tumors.  Columbia University neurosurgeons have now developed a catheter and pump combo that bypasses this blood-brain barrier and pumps cancer-killing chemo directly into a cancer's depths.  This permits the safe perfusion of the tumor with drugs at 1000-fold higher concentrations than if they were introduced intravenously or by mouth.  The semi-permanent pump is installed in the patient's abdomen and its reservoir is refillable via a skin port.   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00599-X/fulltext   #braincancer #chemotherapy #implantablepump #glioma  

As we CROSS into another episode, Michael and Josh explore the world of early gastric cancer and esophageal cancer. Interestingly both these cancers have a higher incidence in Asia and North Africa. Your podcast hosts soon find early detection of these cancers can be difficult, often leading to treatment challenges not seen by other cancer streams, such as bowel or breast cancer. Unlike previous episodes, FLOT4 looks at perioperative chemotherapy and its benefits over the previous incumbent chemotherapy. Before we give anything more away, make sure to listen to this episode to understand the gold standard of care for these cancers. Likes to the trials below!Links to studies discussed in this episode (subscription may be required):CROSS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/fulltexFLOT4: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltextFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael begin their second two-part expedition, this time exploring HER2-positive breast cancer, an area of oncology that has been much like your favourite Instagram or TikTok celebrity: at the forefront of the hottest new trends. Neither Josh nor Mikey have a favourite Instagram or TikTok celebrity because they are old and out of touch, but the shifts in HER2-positive breast cancer may be their favourite oncological TikTok celebrity. For the reasons behind such a stretched analogy, listen on!Links to studies discussed in this episode (subscription may be required):NeoSphere: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltextKATHERINE: https://www.nejm.org/doi/full/10.1056/nejmoa1814017For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Drs Sumanta Pal and Brian Rini discuss front-line treatment of renal cell carcinoma. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968736). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Bevacizumab Plus Interferon-alpha Versus Interferon-alpha Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206 https://ascopubs.org/doi/10.1200/jco.2009.27.18_suppl.lba5019 An updated table of the front-line IO combination RCC studies that have shown an OS advantage https://twitter.com/brian_rini/status/1309609380585844736/photo/1 Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting https://aacrjournals.org/clincancerres/article/26/9/2087/83102/Targeting-PD-1-or-PD-L1-in-Metastatic-Kidney Conditional Survival and Long-term Efficacy With Nivolumab Plus Ipilimumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34180 International Metastatic Renal Cell Carcinoma Database Consortium Criteria https://www.uptodate.com/contents/image?imageKey=ONC%2F116130&topicKey=ONC%2F2984&source=see_link Molecular Correlates Differentiate Response to Atezolizumab (atezo) + Bevacizumab (bev) vs Sunitinib (sun): Results From a Phase III Study (IMmotion151) in Untreated Metastatic Renal Cell Carcinoma (mRCC) https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/presentation/list?q=LBA31 Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-term Follow-up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415096/pdf/nihms-1732721.pdf Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma https://www.nejm.org/doi/10.1056/NEJMoa2035716 The Uromigos Debate: Treatment of Favorable Risk Renal Cancer https://anchor.fm/the-uromigos/episodes/Episode-67-The-Third-Uromigos-Debate---fPD1VEGF-vs-PD1CTLA4-for-front-line-renal-cancer-emjpji Health-Related Quality-of-Life Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus Versus Sunitinib (CLEAR): A Randomised, Phase 3 Study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00212-1/fulltext Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) https://clinicaltrials.gov/ct2/show/NCT03937219 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) https://clinicaltrials.gov/ct2/show/NCT04736706 Twitter poll questions: What magnitude of benefit is required to adopt triplets? OS https://mobile.twitter.com/brian_rini/status/1508450496104783877 What magnitude of absolute PFS benefit vs doublets is required to adopt triplets? https://mobile.twitter.com/brian_rini/status/1508450910506295305 What would be the most convincing endpoint to adopt triplets? https://mobile.twitter.com/brian_rini/status/1508451622564909057 Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436590/ OPtimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC) https://www.kcameetings.org/wp-content/uploads/2021/12/IKCSNA21_TIP8_Chen.pdf

Drs Lidia Schapira and Norah Lynn Henry discuss adjuvant endocrine therapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969538). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update https://ascopubs.org/doi/10.1200/JCO.18.01160 Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients With Breast Cancer https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30666-5/fulltext Acupuncture for Arthralgia-Induced by Aromatase Inhibitors in Patients With Breast Cancer: A Systematic Review and Meta-analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883140/ Long-Term Results From a Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Early Stage Breast Cancer (S1200) https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.12018 Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias https://academic.oup.com/jncics/article/5/2/pkab018/6130825 Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341106/ Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women With Breast Cancer https://maps.cancer.gov/overview/DCCPSGrants/abstract.jsp?applId=10337861&term=CA266012 Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer https://academic.oup.com/oncolo/article/21/5/539/6401566?login=false Effect of a Switch of Aromatase Inhibitors on Musculoskeletal Symptoms in Postmenopausal Women With Hormone-Receptor-Positive Breast Cancer: The ATOLL (Articular Tolerance of Letrozole) Study https://pubmed.ncbi.nlm.nih.gov/20035381/ Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment https://ascopubs.org/doi/full/10.1200/JCO.20.03375 Cohort Study of Adherence to Adjuvant Endocrine Therapy, Breast Cancer Recurrence and Mortality https://www.nature.com/articles/bjc2013116 Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493485/ Caution: Vaginal Estradiol Appears to Be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors https://www.annalsofoncology.org/article/S0923-7534(19)57558-5/fulltext Management of Genitourinary Syndrome of Menopause in Breast Cancer Survivors: An Update https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894268/

  Vidcast:  https://youtu.be/VP_iTWH8NDc   Zapping intermediate risk prostate cancer with high intensity ultrasound using real-time MRI imaging for aiming offers a way to get rid of smaller tumors without the risks of either radiation or surgery.  Urologists at New York's Memorial Sloan Kettering Cancer Center now report the result of their phase 2 clinical trial using this technique for 101 men with intermediate-risk prostate cancer.   The outpatient procedure lasts about 2 hours.  The men, in half-body MRI devices for imaging and mapping the prostatic tumors, were anesthetized and received focused ultrasound beams from several directions sufficient to cook the tumor and a rim of surrounding normal tissue at 140 to 160˚ F.  When the tumor zones were biopsied at 24 months following therapy, 88% of the patients had no evidence of cancer remaining.  The best news: ultrasonic therapy produced none of the urinary incontinence or bowel problems that often follow surgery or radiation therapy.   More studies were underway, but focused ultrasound appears to be an excellent option for men with select prostate cancers.   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00251-0/fulltext#section-3d6acba1-acea-4be2-8dc9-b7e14e5b6583   #ultrasound #prostatecancer #MRI #surgery #radiationtherapy  

Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964337). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources International Myeloma Foundation https://www.myeloma.org/ Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278911/pdf/i0018-5787-52-1-27.pdf Carfilzomib, Lenalidomide, and Dexamethasone Plus Transplant in Newly Diagnosed Multiple Myeloma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714092/ Maintenance With Daratumumab or Observation Following Treatment With Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab and Autologous Stem-Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma (CASSIOPEIA): An Open-Label, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00428-9/fulltext Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 24 Months of Maintenance https://ash.confex.com/ash/2021/webprogram/Paper149024.html Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30525-8/fulltext Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial https://ash.confex.com/ash/2021/webprogram/Paper145097.html Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.21.01935 Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/article/S1470-2045(20)30452-6/fulltext Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2778195 Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-Label, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30578-8/fulltext Carfilzomib With Cyclophosphamide and Dexamethasone or Lenalidomide and Dexamethasone Plus Autologous Transplantation or Carfilzomib Plus Lenalidomide and Dexamethasone, Followed by Maintenance With Carfilzomib Plus Lenalidomide or Lenalidomide Alone for Patients With Newly Diagnosed Multiple Myeloma (FORTE): A Randomised, Open-Label, Phase 2 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/fulltext Lenalidomide, Bortezomib, and Dexamethasone With Transplantation for Myeloma https://www.nejm.org/doi/full/10.1056/NEJMoa1611750

Com o pressuposto de que ainda faltam tratamentos que consigam manter resposta a longo prazo em pacientes com câncer de ovário foi idealizado o Estudo SOLO1/GOG 3004, demonstrando que o olaparibe melhorou significativamente a sobrevida livre de progressão quando comparado com o placebo em pacientes com mutação BRCA, no entanto a sobrevida livre de progressão mediana não foi alcançada.Neste episódio, as dras. Mariana Scaranti e a Daniele Assad discutem o resultado a longo prazo deste importante paper, realizado após 5 anos de acompanhamento.Estuo importante, envolvendo mais de 100 centros em 15 países. As pacientes foram randomizadas para receber olaparibe (300 mg duas vezes ao dia) vs. placebo.Sejam bem vindos ao episódio 99 do Clinical Papers Podcast!Para saber mais sobre o paper, acesse gratuitamente: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltext

Warning!  There is magic contained in this podcast.  Real magic.  The kind of magic that allows you to understand how to manage the axilla in breast cancer patients.    The standard of care approach to management of the axilla in patients with breast cancer has evolved rapidly. While a complete axillary dissection was historically indicated following identification of any positive nodes, that is no longer the case; indeed, axillary dissections are now uncommonly performed. Join Drs. Michael Alvarado, Rita Mukhtar, and Alexa Glencer as they discuss the impact of the ACOSOG Z0011, AMAROS, and ACOSOG Z1071 trials in defining the role of sentinel lymph node dissection and radiotherapy in patients with early-stage breast cancer with limited lymph node involvement as well as the approach when neoadjuvant chemotherapy has been received. Learning Objectives: ·       Describe the study design and results of the ACOSOG Z0011 trial and its impact on the use of sentinel lymph node biopsy as an alternative to complete axillary lymph node dissection in clinically node-negative patients with T1 or T2 breast cancer ·       Describe the study design and results of the AMAROS trial and its implications for use of axillary radiation as an alternative to axillary lymph node dissection for patients with clinically node-negative T1 or T2 breast cancer ·       Understand the risk of lymphedema related to complete axillary lymph node dissection, as demonstrated by the AMAROS trial ·       Describe the study design and results of the ACOSOG Z1071 trial and how interpretation of its subgroup analysis has been applied to our approach of offering sentinel lymph node biopsy as a means of staging the axilla following neoadjuvant chemotherapy in patients with clinical node-positive disease at the time of diagnosis Journal Article Links: ACOSOG Z0011: https://jamanetwork.com/journals/jama/article-abstract/2653737 AMAROS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70460-7/fulltext ACOSOG Z1071: https://jamanetwork.com/journals/jama/fullarticle/1748149%20 Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Drs Schapira and Gillespie begin this series by reviewing the current research on radiation options for early-stage breast cancer and how to discuss treatment options with patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963162). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Radiation Therapy for the Whole Breast: Executive Summary of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline https://www.practicalradonc.org/article/S1879-8500(18)30051-1/fulltext Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526720/ Hypofractionated Breast Radiotherapy for 1 Week Versus 3 Weeks (FAST-Forward): 5-Year Efficacy and Late Normal Tissue Effects Results From a Multicentre, Non-inferiority, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30932-6/fulltext Partial-Breast Radiotherapy After Breast Conservation Surgery for Patients With Early Breast Cancer (UK IMPORT LOW trial): 5-Year Results From a Multicentre, Randomised, Controlled, Phase 3, Non-inferiority Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31145-5/fulltext External Beam Accelerated Partial Breast Irradiation Versus Whole Breast Irradiation After Breast Conserving Surgery in Women With Ductal Carcinoma In Situ and Node-Negative Breast Cancer (RAPID): A Randomised Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32515-2/fulltext Once Daily Versus Twice Daily External Beam Accelerated Partial Breast Irradiation: A Randomized Prospective Study https://www.redjournal.org/article/S0360-3016(20)34566-1/fulltext Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-term Results of the Randomized Phase III APBI-IMRT-Florence Trial https://ascopubs.org/doi/10.1200/JCO.20.00650 Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2422117 De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) https://clinicaltrials.gov/ct2/show/NCT04852887 Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-term Follow-up of CALGB 9343 https://ascopubs.org/doi/10.1200/JCO.2012.45.2615 PRIME II Investigators. Breast-Conserving Surgery With or Without Irradiation in Women Aged 65 Years or Older With Early Breast Cancer (PRIME II): A Randomised Controlled Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71221-5/fulltext Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 https://jamanetwork.com/journals/jama/fullarticle/2653737 Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer (EORTC 10981-22023 AMAROS): A Randomised, Multicentre, Open-Label, Phase 3 Non-inferiority Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70460-7/fulltext Regional Lymph Nodes Radiation and Breast Cancer Related Lymphedema: Where We Stand https://www.redjournal.org/article/S0360-3016(21)00165-6/fulltext Event-Free Survival With Pembrolizumab in Early Triple-Negative Breast Cancer https://www.nejm.org/doi/10.1056/NEJMoa1910549

Welcome to episode 9 of IMPACT Medicom's podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom's Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer. Our Guests:Dr. Taymaa May Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada's (GOC) Annual General Meeting and is a member of GOC's board of directors. Dr. May's research focuses on surgical innovation and translational research in ovarian cancer.Dr. James Bentley Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.Links:SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltextCorrelation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltextThis podcast episode was sponsored by AstraZeneca Canada and Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Abrindo a séries dos BIOTalks especiais com os melhores artigos publicados do ano o Dr. Fernando Sabino e a Dra. Renata D'Alpino destacam os 3 principais artigos em tumores gastro-intestinais publicados em 2021. Link Artigo 1 - https://www.nejm.org/doi/full/10.1056/NEJMoa2032125 Link Artigo 2 - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/fulltext Link Artigo 3 - https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30555-6/fulltext Mandem suas críticas, elogios e/ou sugestões: bioeducation@bioeducation.com.br Siga a BIO no Instagram: @bioeducation Siga a BIO no Twitter: @OncologyBio Siga a BIO no Facebook: BIO - Brazilian Information Oncology

Aju Mathew (Malankara Orthodox Syrian Church Medical College and Hospital, Kerala, India) discusses his Review on financial toxicity in cancer care in India. Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00468-X/fulltext

David Pinato (Imperial College London, Hammersmith Hospital, London, UK) discusses his Article on prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection.Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00573-8/fulltext

James Glasbey (UK NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK) discusses his Article on the effect of COVID-19 pandemic lockdowns on planned cancer surgery. Read the full paper:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00493-9/fulltext

Dois famosos estudos sobre o tema, STARS e ROSEL, mostraram uma maior sobrevida após radioterapia ablativa estereotáxica (SBRT) quando comparada com cirurgia para câncer de pulmão de células não pequenas em estágio inicial operável (NSCLC), entretanto, essa análise teve muitas limitações.Neste episódio discutimos um estudo que mostra os resultados de longo prazo do estudo STARS revisitado. Nesta “nova versão”, o grupo SBRT foi reconstituído com um tamanho de amostra maior, com uma cirurgia mais atual com menos morbi mortalidade pós-operatória.E agora? Será que esses resultados mais atuais, apesar de positivos, mudaram a conduta frente a essa situação?Saiba mais sobre Propensity Score Matching neste episódio!Sejam bem-vindos ao episódio 90 do Clinical Papers Podcast!Para saber mais sobre o paper, acesse: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00401-0/fulltextEsse episódio teve o apoio da PMIScience

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30388-0/fulltext

The ICCL has found another horrible, civil liberty limiting bill to fully support; the government brings in antigen testing, in the most cack-handed fashion imaginable; and maybe the real solution to online misinformation is simply acting in a trustworthy fashion.    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30388-0/fulltext

Publicado agora em abril de 2021, o PRODIGE 23 traz em seu resumo a conclusão de que, esse esquema de quimioterapia neoadjuvante deve mudar a prática clínica. Mas, como diz o Mário Sérgio Cortella: Será?!?!Ouça esse episódio 85 do Clinical Papers Podcast e descubra que a adição de irinotecano ao TNT com FOLFOX pode ser “demais” para melhorar os resultados relacionados ao tratamento de câncer de reto localmente avançado.Com uma revisão !TOP! sobre o tratamento de câncer de reto, os drs. Ranyell Spencer, Tiago Biachi e Allan Pereira mostram o que está nas entrelinhas desse importante estudo.Sejam bem-vindos ao episódio 85 do Clinical Papers PodcastPara saber mais sobre o paper, acesse: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00079-6/fulltext

O'Toole's piece - https://www.irishtimes.com/opinion/fintan-o-toole-ian-bailey-deflects-us-from-the-reality-of-violent-misogyny-1.4624916Projected deaths in UK from missed healthcare - https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30388-0/fulltextHPSC's last report on the weekly COVID-19  epidemiology   - https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/epidemiologyofcovid-19inirelandweeklyreports/COVID-19%20Weekly%20Report_Slidset_HPSC_%20Week_18_WEB_20210511.pdfIrish COVID-19 hub - https://covid19ireland-geohive.hub.arcgis.com/Dutch COVID-19 hub - https://coronadashboard.government.nl/landelijk/varianten

Ian Bailey is back in the news, with both Fintan O'Toole and Sinead O'Connor getting involved; and the COVID-19 CFR and the need to discuss how many deaths are acceptable when we reopen. O'Toole's piece - https://www.irishtimes.com/opinion/fintan-o-toole-ian-bailey-deflects-us-from-the-reality-of-violent-misogyny-1.4624916 Projected deaths in UK from missed healthcare - https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30388-0/fulltext HPSC's last report on the weekly COVID-19  epidemiology   - https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/epidemiologyofcovid-19inirelandweeklyreports/COVID-19%20Weekly%20Report_Slidset_HPSC_%20Week_18_WEB_20210511.pdf Irish COVID-19 hub - https://covid19ireland-geohive.hub.arcgis.com/ Dutch COVID-19 hub - https://coronadashboard.government.nl/landelijk/varianten

What’s in the OncTimesTalk, May 2021 Edition? New clinical findings on: Nivolumab in gastro-esophageal cancer, CDK4/6 inhibition for breast cancer, COVID-19 vaccination limitations, sitagliptin/graft-versus-host disease, breast cancer individualization, neo-adjuvant chemotherapy for rectal cancer. Featuring: Ronan Kelly (Austin TX), Erica Mayer (Boston MA), Sibylle Loibl (Frankfurt, Germany), Shabir Madhi (Johannesburg South Africa) and Thierry Conroy (Nancy, France). Interviews in this edition: Ronan J Kelly MD MBA, Baylor University Medical Center, Dallas Adjuvant Nivolumab “Practice Changing” in Resected Gastroesophageal Cancer Ronan Kelly tells OncTimesTalk about a big reduction in the risk of death, and doubling of median disease-free survival, from using nivolumab as adjuvant therapy for patients with esophageal, and gastro-esophageal junction, cancers after chemoradiotherapy plus surgery in the placebo-controlled phase-three CheckMate 577 study. https://www.nejm.org/doi/full/10.1056/NEJMoa2032125 Erica L. Mayer MD, Dana-Farber Cancer Institute, Boston, MA Palbociclib Added No Benefit to Breast Cancer Adjuvant Endocrine Therapy Erica Mayer discusses the PALLAS study findings with OncTimesTalk that adding the CDK 4/6 inhibitor palbociclib to endocrine therapy failed to improve invasive disease-free survival among patients with early breast cancer despite its proven efficacy in metastatic disease. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30642-2/fulltext Breast Cancer: A Guide to Therapy Individualization  Sibylle Loibl, Professor of Obstretrics and Gynaecology, University of Frankfurt, CEO and Chair, German Breast Group. Sibylle Loibl discusses her expert panel’s findings with OncTimesTalk about optimizing the many powerful methods for managing breast cancer to individualize treatment. “Future research in breast cancer will focus not only on new drugs, but even more on the individualization of therapy for every single tumor in every single patient,” she wrote in “The Lancet”. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32381-3/fulltext Sherif S. Farag MD PHD, Director of the Stem Cell Transplant and Cellular Therapy, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, in Indianapolis Sitagliptin Reduced Graft Versus Host Disease in Stem Cell Transplantation A non-randomized 36-patient phase-two clinical study found a big reduction in acute graft-versus-host disease after adding the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (a long established antiglycemic agent) to immunosuppression for allogeneic stem-cell transplantation.  Sherif Farag discusses the study findings with OncTimesTalk. http://www.nejm.org/doi/full/10.1056/NEJMoa2027372 Shabir A. Madhi PhD, Professor of Vaccinology and Director of the Vaccines & Infectious Diseases Analytics Research Unit at the University of Witwatersrand in Johannesburg, Co-Director of African Leadership in Vaccinology Expertise. SARS-CoV-2 Vaccine Was Ineffective Against B.1.351 (“South African”) Variant A “first-generation” vaccine for COVID-19 failed to prevent mild or moderate disease caused by the B.1.351 coronavirus variant in South Africa in a randomized, double-blind, controlled trial of the ChAdOx1 nCoV-19 vaccine among relatively young adults. Shabir Madhi tells OncTimesTalk, however, that vaccination with such first-generation vaccines should still protect against severe disease and death from the new variant because T-cell responses had been preserved in the South African variant. https://www.nejm.org/doi/full/10.1056/NEJMoa2102214 Thierry Conroy MD, Professor, Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54519 Vandoeuvre-lès-Nancy, France Neoadjuvant Chemotherapy Before Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer A multi-center, randomized, open-label, phase-three trial has shown that outcomes for patients with rectal cancer can be improved still further by using neoadjuvant chemotherapy before the current standard of care (chemo-radiotherapy and surgery).  Professor Thierry Conroy, from the Cancer Institute in Nancy, gives OncTimesTalk the details on why they decided to try an additional treatment and the benefit it brought. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00079-6/fulltext

Sejam bem vindos ao Clinical Papers Podcast!Neste episódio, iremos discutir um paper publicado agora em fev/2021 na LANCET Oncology: O Estudo PRODIGE 7. Nele, seus autores, avaliaram o papel da HIPEC, após a realização da cirurgia de citorredução completa, em pacientes com metástase peritoneal de origem colorretal. Entenda como os autores pensam e qual o racional deste importante Estudo.Para saber mais sobre o paper, acesse: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30599-4/fulltext

O tratamento padrão para o adenocarcinoma de reto localmente avançado é radioterapia neoadjuvante (50,4GY/28 dias) +- QT adjuvante após a cirugia (TME).O uso de um esquema com radioterapia de curso rápido, hipofracionada, pode antecipar o uso de quimioterapia e diminuir o risco de progressão sistêmica com melhora em sobrevida..Com um modelo ousado de tratamento, o RAPIDO trial foi criado. No entanto, alguns erros metodológicos graves põem em xeque os resultados deste importante estudo. Esse é o último episódio de 2020!Sejam muito bem-vindos ao Clinical Papers Podcast! Para saber mais sobre o paper acesse:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30555-6/fulltext

In this episode, Dr Alok Khorana talks about the evolution of treatment for patients with cancer-associated thrombosis, Dr Ander Cohen discusses the importance of treatment satisfaction in these patients and Dr Jeff Weitz and Dr Jan Beyer-Westendorf discuss the management of a patient with colorectal cancer and incidental pulmonary embolism Further Details: • Data showing the increased risk of VTE recurrence in patients with cancer-associated thrombosis is available here: https://ashpublications.org/blood/article/100/10/3484/106282/Recurrent-venous-thromboembolism-and-bleeding • The dedicated trials on NOACs in cancer-associated thrombosis can be accessed here for edoxaban (https://pubmed.ncbi.nlm.nih.gov/31733403/), rivaroxaban (https://pubmed.ncbi.nlm.nih.gov/31995662/) and apixaban (https://pubmed.ncbi.nlm.nih.gov/28837207/, https://pubmed.ncbi.nlm.nih.gov/32223112/) • More details on the patient reported outcomes in COSIMO can be found here: https://pubmed.ncbi.nlm.nih.gov/32877956/ • COSIMO baseline characteristics and clinical outcomes are described here: https://ashpublications.org/blood/article/134/Supplement_1/2161/427953/Baseline-Characteristics-and-Clinical-Outcomes • The ISTH 2018 guidelines on cancer-associated thrombosis can be found here: https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14219 • The ASCO 2019 guidelines on cancer-associated thrombosis can be found here: https://ascopubs.org/doi/10.1200/JCO.19.01461 • The ITAC 2019 guidelines on cancer-associated thrombosis can be found here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30336-5/fulltext • The NCCN 2020 guidelines on cancer-associated thrombosis can be found here: https://www.google.com/url?client=internal-element-cse&cx=007894372670309631110:vocdaeamxuy&q=https://www.nccn.org/Common/FileManager.ashx%3FfileManagerId%3Db0461271-ae6f-455a-bbb9-a637326abe49&sa=U&ved=2ahUKEwiTm5-0kcvsAhWNqZ4KHZinDsMQFjAAegQIBhAB&usg=AOvVaw1lR7Ua6h1mBxVItb_BHMe9 • The ESC 2019 guidelines on the diagnosis and management of acute pulmonary embolism can be found here: https://academic.oup.com/eurheartj/article/41/4/543/5556136 • For anticoagulant dosing information, see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and low molecular weight heparin (https://www.ema.europa.eu/documents/product-information/inhixa-epar-product-information_en.pdf) (https://www.ema.europa.eu/documents/product-information/arixtra-epar-product-information_en-1.pdf) (https://www.medicines.org.uk/emc/product/4247/smpc#gref) (https://www.medicines.org.uk/emc/product/1695#gref) Recording approval code: PP-M_RIV-ALL-0157-1; Shownotes approval code: PP-M_RIV-ALL-0158-1

Final OS results are now available for IDEA - 3 vs. 6 months of adjuvant chemotherapy for colon cancer: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30527-1/fulltext Keynote-177 (pembrolizumab for MSI-H/dMMR metastatic colorectal cancer) was presented at ASCO, but interim results are now published as well: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699

O tratamento padrão para o CEC de canal anal é praticamente o mesmo desde a década de 70. Muito tem sido feito no sentido de se tentar substituir a mitomicina por cisplatina nesse cenário, no entanto os resultados ainda são conflitantes.O ACT II Trial foi um estudo com modelo fatorial 2 × 2, onde os pacientes eram randomizados em 4 grupos: mitomicina ou cisplatina, com fluorouracil e radioterapia; com ou sem dois cursos de QT de manutenção. .Com mais de 900 pacientes incluídos, esse foi um estudo negativo, mas que tem influenciado muito a conduta para o tratamento desta doença. Sejam muito bem-vindos ao Clinical Papers Podcast! Para saber mais sobre o paper acesse: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70086-X/fulltext

Ao contrário dos sarcomas de extremidade, a eficácia da radioterapia nos casos de sarcoma retroperitoneal ainda não está estabelecida. Com o objetivo de avaliar o impacto da radioterapia pré-operatória associada à cirurgia versus cirurgia isolada na sobrevida livre de recorrência abdominal, o STRASS Trial foi idealizado. .....Também conhecido como EORTC-62092, este estudo incluiu 31 instituições localizadas em 13 países da Europa e América do Norte. Incluindo apenas pacientes com idade ≥18 anos portadores de sarcoma retroperitoneal primário localizado e passíveis de ressecção, este estudo teve resultado negativo e não rejeitando a hipótese nula, com sobrevida livre de recorrência abdominal mediana de 4,5 anos no grupo de radioterapia + cirurgia e 5,0 anos no grupo apenas de cirurgia (p = 0,95)......Os autores concluíram então que “A radioterapia pré-operatória não deve ser considerada como tratamento padrão para o sarcoma retroperitoneal.”.....No entanto os Drs. Ranyell Spencer e Elton Leite discutiram esse paper e discordaram dessa conclusão diante de vieses sistemáticos do estudo......Sejam bem-vindos a mais um episódio do Clinical Papers Podcast!.....Não perca esta discussão e saiba mais sobre o paper pelo link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30446-0/fulltext

Neue Studie: Früherer Beginn rettet Leben. Weitere Informationen: 1. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30398-3/fulltext 2. https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(15)00128-X.pdf 3. https://www.aerzteblatt.de/nachrichten/115589/Mammografie-ab-dem-40-Lebensjahr-senkt-in-Studie-Brustkrebssterblichkeit Mehr Informationen zum Podcast unter: https://www.medical-tribune.de/medaudio/

Náuseas e vômitos são os sintomas mais frequentes de um paciente que faz quimioterapia. O estudo J-FORCE avaliou o uso da Olanzapina (5mg) adicionada ao esquema padrão de tratamento para combater e prevenir náuseas e vômitos em pacientes submetidos a QT com cisplatina. Esse foi um estudo japonês, randomizado publicado na Lancet em 2019. Com um resultado positivo, acreditamos que esse paper tenha mudado conduta e possa ajudar a muitos pacientes durante o seu tratamento. Saiba mais sobre esse tema com Tiago e Ranyell, e, quem sabe, leve isso para sua prática clínica. Seja muito bem vindo ao Clinical Papers Podcast! Para ter acesso ao paper na íntegra, acesso o link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30678-3/fulltext

Publicado na LANCET Oncol em 2018, o PORTEC-3 Trial avaliou o papel da QT (radiossensibilizante e adjuvante) para o tratamento de pacientes com tumor de endométrio de alto risco. O estudo teve como objetivo primário dois endpoints que seriam: Sobrevida global e Livre de falha (óbito por doença ou recorrência). Após os autores randomizarem mais de 650 mulheres, com um seguimento de 60.2 meses, o estudo foi considerado negativo para o benefício dessa estratégia mais “agressiva” vs. radioterapia no que se referiu, principalmente, a sobrevida global. Em especial, no final do episódio Ranyell e Tiago discutem o papel do médico na decisão compartilhada com os pacientes, além da necessidade de publicação de estudos negativos. Procure-nos nas redes sociais e faça parte desse projeto! Você está no Clinical Papers Podcast! Para ter acesso ao paper na íntegra, acesso o link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30079-2/fulltext

Cetuximabe e Bevacizumabe têm demonstrado aplicabilidade clínica no câncer colorretal. A maioria dos estudos no entanto utiliza a associação dessas drogas com esquemas contendo oxaliplatina. O FIRE-3 foi um estudo publicado na THE LANCET Oncology em 2014 que comparou o uso de ambas as terapias com FOLFIRI avaliando como endpoint primário taxa de resposta ao RECIST para pacientes EC IV KRAS wild-type. Não se preocupe com esses nomes esquisitos! Eu e Tiago explicaremos pra você! Esse é o primeiro de dois estudos que falaremos com o objetivo de tratar do tema “lateralidade em câncer colorretal”. Veja também como você deve se comportar diante de um estudo patrocinado. O que isso pode implicar em análise e divulgação de dados. Para saber mais sobre esse paper, acesse o link abaixo e tenha acesso grátis na íntegra! https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70330-4/fulltext Siga-nos nas redes sociais e faça seus comentários! Sejam muito bem vindo a mais um episódio do Clinical Papers Podcast!

We discuss 4 recent publications from the world of sleep science with Dr Jonathan Cedernaes. Discussing weekend sleep recovery, shift work & cancer, daylight saving time, and the inter-individuality in light response of the human circadian system Publication discussed in this episode: 1) Ad libitum Weekend Recovery Sleep Fails to Prevent Metabolic Dysregulation during a Repeating Pattern of Insufficient Sleep and Weekend Recovery Sleep.  https://www.cell.com/current-biology/fulltext/S0960-9822(19)30098-3 2) Why Should We Abolish Daylight Saving Time?  https://journals.sagepub.com/doi/full/10.1177/0748730419854197 3) Shift work and cancer Carcinogenicity of shift work https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30455-3/fulltext Night shift work and risk of breast cancer in women: the Generations Study cohort https://www.nature.com/articles/s41416-019-0485-7 4) High sensitivity and interindividual variability in the response of the human circadian system to evening light  https://www.pnas.org/content/116/24/12019   This episode's guest: Jonathan Cedernaes MD, PhD is a senior researcher at Uppsala University where he completed both his medical degree and his PhD in the Department of Neuroscience. LinkedIn: https://www.linkedin.com/in/jonathan-cedernaes-176b3159 Twitter: https://twitter.com/JCedernaes Sleep Science Facebook Group: https://www.facebook.com/groups/495466987134152/ More Resources: Society for Research on Biological Rhythms: https://srbr.org/ Sleep 4 Performance podcast with Sean Cain: https://bit.ly/2nGEhme Episode Homepage: https://sleepjunkies.com/research-roundup-sep-2019/ More Episodes:

We discuss 4 recent publications from the world of sleep science with Dr Jonathan Cedernaes. Discussing weekend sleep recovery, shift work & cancer, daylight saving time, and the inter-individuality in light response of the human circadian system Publication discussed in this episode: 1) Ad libitum Weekend Recovery Sleep Fails to Prevent Metabolic Dysregulation during a Repeating Pattern of Insufficient Sleep and Weekend Recovery Sleep.  https://www.cell.com/current-biology/fulltext/S0960-9822(19)30098-3 2) Why Should We Abolish Daylight Saving Time?  https://journals.sagepub.com/doi/full/10.1177/0748730419854197 3) Shift work and cancer Carcinogenicity of shift work https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30455-3/fulltext Night shift work and risk of breast cancer in women: the Generations Study cohort https://www.nature.com/articles/s41416-019-0485-7 4) High sensitivity and interindividual variability in the response of the human circadian system to evening light  https://www.pnas.org/content/116/24/12019   This episode's guest: Jonathan Cedernaes MD, PhD is a senior researcher at Uppsala University where he completed both his medical degree and his PhD in the Department of Neuroscience. LinkedIn: https://www.linkedin.com/in/jonathan-cedernaes-176b3159 Twitter: https://twitter.com/JCedernaes Sleep Science Facebook Group: https://www.facebook.com/groups/495466987134152/ More Resources: Society for Research on Biological Rhythms: https://srbr.org/ Sleep 4 Performance podcast with Sean Cain: https://bit.ly/2nGEhme Episode Homepage: http://sleepjunkies.com/research-roundup-sep-2019/ More Episodes:

Neste mais novo episódio do Clinical Papers discutimos o REGATTA study. Esse paper, que teve um resultado negativo, praticamente definiu a conduta no câncer gástrico metastático. A grande pergunta desse estudo publicado na LANCET em 2016 foi se a gastrectomia profilática em pacientes metastáticos teria impacto em sobrevida. Após analisados em torno de 175 pacientes, o estudo foi finalizado porque preencheu critérios de análise interina por futilidade. Interessante foi ver que alguns pacientes que iniciaram QT pré operatória tiveram resposta completa e foram eventualmente curados! Não perca mais este episódio! Tenha acesso ao paper pelo link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00553-7/fulltext

Fontes: http://www.huffpostbrasil.com/entry/genetically-modified-seed-patent-report_n_2678837 http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70134-8/fulltext http://www.etcgroup.org/sites/www.etcgroup.org/files/publication/656/01/etctop10seed_october2007.pdf

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession

Ab heute bringen wir jeden Samstag eine neue Folge unseres brandneuen Podcasts. Ihr dürft euch auf ein spannendes Thema freuen. Wir analysieren den Film "What the Health?" und stellen uns die Frage: Müssen wir jetzt alle vegan werden⁉ Quellen: Bley, C.-H., Centgraf, M., Cieslik, A., Hack, J., & Hohloch, L. (2015). I care Anatomie, Physiologie. Thieme Verlag. European Food Safety Authority (EFSA). Dioxins and PCBs. Verfügbar auf: https://www.efsa.europa.eu/en/topics/topic/dioxins-and-pcbs Hessisches Ministerium für Umwelt, ländlichen Raum und Verbraucherschutz (2006). Ergebnisse der Amtlichen Lebensmittelüberwachung in Hessen für das Jahr 2005. Verfügbar auf: http://starweb.hessen.de/cache/hessen/lebensmitteljahresbericht_2005.pdf International Agency for Research on Cancer (2015). Carcinogenicity of consumption of red and processed meat. The Lancet Oncology, 18(7), 835-980. Verfügbar auf: http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(15)00444-1.pdf Mayes, P. (1993). Intermediary Metabolism of Fructose. The American Journal of Clinical Nutrition. World Health Organization (WHO) (2017). The top 10 causes of death. Verfügbar auf: http://www.who.int/mediacentre/factsheets/fs310/en/index1.html World Health Organization (WHO) (2017). Noncommunicable diseases. Verfügbar auf: http://www.who.int/mediacentre/factsheets/fs355/en/ World Health Organization (WHO) (2016). Diabetes. Verfügbar auf: http://www.who.int/mediacentre/factsheets/fs312/en/ www.elaecoaching.de

In this episode of MyPal Dr Amara Nwosu provides an overview of the health secretary's recent speech to the Health Service Journal which outlined the potential role of technology in healthcare. Patient power: threat or opportunity? Health Secretary's speech on the opportunities offered by the shift to a patient-powered, technologically advanced health service. Department of Health and The Rt Hon Jeremy Hunt MP Health Service Journal, Barber-Surgeons‘ Hall, London https://www.gov.uk/government/speeches/patient-power-threat-or-opportunity Smart patients Emma Hill, Lancet Volume 15, No. 2, p140–141, February 2014. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70044-0/abstract The Patient Will See You Now: The Future of Medicine is in Your Hands by Eric Topol http://www.amazon.com/The-Patient-Will-See-You/dp/0465054749 Patient reported outcomes http://sites.duke.edu/rethinkingclinicaltrials/patient-reported-outcomes/ Use of an electronic patient-reported outcome measurement system to improve distress management in oncology Palliat Support Care. 2014 Feb; 12(1): 69–73. Sophia K. Smith, Krista Rowe, Amy P. Abernethy http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066540/ Copyright Dr Amara Nwosu, KingAmi Media 2015. www.amaranwosu.com Music by Bensound www.bensound.com/royalty-free-music

On today’s show, we take a good look at the recent WHO evaluation of red and processed meats, which resulted in them being classified as carcinogens by the IARC. What exactly did they say? What do the classifications mean? Did the media get it right? What are the takeaways? All that, plus “Eternal Summer” in the Shinrin-yoku segment, “More than you think” in the Moment of Paleo, and compelling "Thoughts About Silence" in the After the Bell segment. Links for this episode:New! Full List of Recommended Books & AudiobooksOur Facebook Community: News Hunters & Gatherers, Post Your Links Here!This episode's homepage with sectioned show notes & moreGlobesity: Fat's New Frontier - YouTubeGlobesity: Fat's New Frontier - Trailer - YouTubeJourneyman Pictures : documentaries : Globesity: Fat's New FrontierCarcinogenicity of consumption of red and processed meat - The Lancet OncologyMeat and Cancer: The W.H.O. Report and What You Need to Know - The New York TimesBad Day For Bacon: Processed Meats Cause Cancer, WHO Says : The Salt : NPRProcessed meats do cause cancer - WHO - BBC NewsRed Meats Linked to Cancer, Global Health Group Says - WSJProcessed meats rank alongside smoking as cancer causes – WHO | Society | The GuardianBacon and other processed meats can cause cancer, experts say | ReutersDo I Have to Stop Eating Meat? Key Questions About WHO Group Report - NBC NewsProcessed meat and cancer – what you need to know - Cancer Research UK - Science blogBacon, Hot Dogs, and Processed Meats Cause Cancer, WHO Says | Mother JonesBacon Causes Cancer? Sort of. Not Really. Ish. | WIREDWHO Says Red Meat Probably Causes Cancer - The AtlanticDo bacon and red meat cause cancer? Evidence and answers.U.N. agency links bacon, hot dogs, other processed meat to cancer | The Seattle TimesWHO says hot dogs, sausages cause cancer. Chicagoans say we are so dead. - Chicago TribuneWhole Health Source: Do Processed and Red Meat Cause Cancer?North American Meat InstituteWorld Health Organisation, meat & cancer | Zoë HarcombePsychological comments: Bacon sandwich hysteriaBacon causes cancer. Should you panic? | GristRed Meat and Colorectal Cancer: A Quantitative Update on the State of the Epidemiologic Science - Journal of the American College of Nutrition - Volume 34, Issue 6Cancer Vegetarianism & DietDisrupted seasonal biology impacts health, food security and ecosystems | Proceedings of the Royal Society of London B: Biological Sciences'Eternal summer' due to artificial light and heating is bad for us, experts say - ScienceAlertCranking the thermostat can leave you ill, here's why News - The Weather NetworkTEDxAmazonia - Gordon Hempton | wants to save silence from extinction - Nov.2010 - YouTubeSponsored in part by PuraKai. Visit purakai.com to shop for eco-friendly clothing and stand-up paddle boards. Be sure to use coupon code "latest in paleo" for 15% off all clothing purchases.